PF-04634817: Clinical Trials

5 completed, 1 terminated. 4 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 2	2	Completed 1, Terminated 1

Follow this drug Literature Review of PF-04634817 trials Research Report on PF-04634817

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema Ranibizumab, Placebo, PF-04634817 - Macular Edema, Diabetic	Phase 2	Terminated	Pfizer	199	2013-11-01	2016-10-17
PF-04634817 Renal Impairment Study PF-04634817 - Renal Insufficiency	Phase 1	Completed	Pfizer	32	2013-05-10	2024-03-01
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy PF-04634817, Placebo - Diabetic Nephropathy	Phase 2	Completed	Pfizer	226	2012-12-01	2015-10-21
A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers PF-04634817 - Healthy	Phase 1	Completed	Pfizer	13	2010-10-01	2011-02-02
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects PF-04634817 - Healthy	Phase 1	Completed	Pfizer	48	2010-06-01	2011-06-08
First In Human Study Of Increasing Oral Doses Of PF-04634817 PF-04634817 Placebo, PF-04634817 - Healthy	Phase 1	Completed	Pfizer	27	2010-04-01	2010-10-13

Conditions studied

Diabetic Nephropathies (2)  ·  Albuminuria (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Diabetic Retinopathy (1)  ·  Macular Edema (1)  ·  Renal Insufficiency (1)

Sponsors

Pfizer (6)

Countries

United States (6)  ·  Germany (2)  ·  Poland (2)  ·  Romania (2)  ·  Argentina (1)  ·  Australia (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  Hong Kong (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Moldova (1)

Results publications

PMID 29847672, PMID 31566438